GE Healthcare is a leading provider of medical imaging, monitoring, biomanufacturing, and cell and gene therapy technologies. GE Healthcare enables precision health in diagnostics, therapeutics and monitoring through intelligent devices, data analytics, applications and services. With over 100 years of experience and leadership in the healthcare industry and more than 50,000 employees globally, GE Healthcare helps healthcare providers, researchers and life sciences companies in their mission to improve outcomes for patients around the world.  Follow us on Facebook, LinkedIn, Twitter and The Pulse for latest news, or visit our website www.gehealthcare.com for more information.

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives and a leader in Women’s Health.

Roche Sequencing Solution of Roche is focused on developing novel technologies and products to support innovation in clinical research applications. Part of Roche Sequencing Solutions, the Harmony® prenatal test is a non-invasive screening test for pregnant women that can be used as early as 10 weeks of pregnancy. By evaluating fetal cell-free DNA found in maternal blood, including accurate measurement of the fetal fraction of cfDNA, the test assesses the probability of Trisomy 21 (Down syndrome) and other common fetal chromosomal conditions. The results are intended for prenatal screening and are not intended to be the sole basis for diagnosis. The Harmony® prenatal test has been used to guide clinical care in over 1,8 million pregnancies worldwide. For more information, visit .

PerkinElmer is a global company focused on improving the health and safety of people and their environment. Within the field of fetal and maternal healthcare, PerkinElmer offers complete screening solutions including instrumentation, reagents and risk calculation software for early detection of pregnancy related anomalies.

PerkinElmer was chosen as the principal screening partner for ASPRE. Throughout the study, the PerkinElmer DELFIA^® Xpress PlGF 1-2-3^TM assay was used as an aid in screening for pre-eclampsia in conjunction with maternal history, mean arterial blood pressure (MAP) measurement, and uAD (Uterine Artery Doppler). Also, PerkinElmer partners with FIGO’s Non-Communicable Disease (NCD) Committee to help develop guidelines and practice recommendations on pre-eclampsia prevention.

PerkinElmer has now launched the Vanadis^TM NIPT system which is an automated non-sequencing, non-PCR based solution for cfDNA analysis. PerkinElmer offers an easy to use, cost-effective, high-throughput screening test to help facilitate wider access to non-invasive prenatal testing for pregnant women.

Maternal fetal products availability and claims may differ from country to country based on regulations and product approvals. Please check availability with your local distributor.

Illumina is the leading technology provider for noninvasive prenatal testing (NIPT)—enabling health care professionals and expectant parents to be informed about their pregnancy. Illumina is dedicated to improving health through genomics.

Canon Medical offers a full range of diagnostic medical imaging solutions including CT, X-Ray, Ultrasound and MRI, across the globe. As of December 2016, Canon Medical became a member of the Canon Group. In line with our continued Made For life philosophy, patients are at the heart of everything we do. Our mission is to provide medical professionals with solutions that support their efforts in contributing to the health and wellbeing of patients worldwide. Our goal is to deliver optimum health opportunities for patients through uncompromised performance, comfort and safety features.

At Canon Medical we work hand in hand with our partners – our medical, academic and research community. We build relationships based on transparency, trust and respect. Together as one, we strive to create industry-leading solutions that deliver an enriched quality of life.

Founded in 1991, Mindray is one of the leading global providers of medical devices and solutions. Firmly committed to our mission of “advance medical technologies to make healthcare more accessible”, we are dedicated to innovation in Medical Imaging System.

Mindray possesses a sound global R&D, marketing and service network. Inspired by the needs of our customers, we adopt advanced technologies and transform them into accessible innovation, bringing healthcare within reach. Today, Mindray’s products and services can be found in healthcare facilities in over 190 countries and regions.

B·R·A·H·M·S GmbH, part of Thermo Fisher Scientific, investigates, develops and manufactures novel diagnostic testing procedures to improve early diagnosis and treatment of life threatening diseases. With high-quality immunodiagnostic tests for prenatal screening, cardiovascular, pulmonary, and cancer disorders as well as for sepsis, the company contributes to the creation of a healthier future – to the greatest advantage for medical professionals and patients.

In future simple and economic blood tests will be of great importance for an early detection and successful treatment of diseases. With our know-how and technologies we are confident to play an active role in this future: Our products provide important information to clinicians and laboratories in more than 130 countries worldwide, supporting their clinically and economically relevant decisions.

The B·R·A·H·M·S KRYPTOR platforms and the B·R·A·H·M·S biomarkers for prenatal screening are CE certified and approved by the Fetal Medicine Foundation (FMF), the portfolio comes up to the quality standards of the FMF since 1999.

At Philips, we look beyond technology to the experiences of patients, providers and caregivers across the health continuum, from healthy living to prevention, diagnosis, treatment and home care. We unlock insights leading to meaningful innovations from hospital to home.  Our integrated solutions – comprising systems, smart devices, software and services – combine broad and deep clinical expertise, technology and services, actionable data, consultative new business models and partnerships.  Together, with our customers, we can transform how care is delivered and experienced.

astraia software is based in Munich, Germany and was founded in 2000. The aim was to develop an independent database application that would cover all aspects of obstetrics and gynaecology to the highest medical standard.

Since then, astraia has established its position as market leader and pioneer in obstetric and gynaecological database applications. The company's success is due to a close working relationship with leading experts worldwide and highly flexible adaptation to market requirements . In many countries astraia is also represented by local sales partners to assure first class customer service. The astraia software solutions provide healthcare professionals with structured data entry screens that guide through the examination, making sure nothing is missed . All data(including measurements and images) is saved securely . It can be accessed any time for later reference or queried for studies and further analysis . Creating a complete and appealing report only takes a few mouse clicks .

From carrier screening, serum screening, NIPT, diagnostic testing, and hereditary cancer testing, Integrated Genetics—a member of the LabCorp Specialty Testing Group—offers a comprehensive genetic testing menu. With over 1,700 patient service centers, the largest commercial genetic counseling network, and an online cost estimator, Integrated Genetics helps you understand DNA.

Natera is a global leader in cell-free DNA genetic testing. Natera operates an ISO 13485-certified and CAP-accredited CLIA laboratory in the United States. Products include: Spectrum™, a preimplantation genetic test used in vitro fertilization (IVF); Anora™ to understand the genetic causes of a pregnancy loss; Horizon™ to detect the presence of single  gene mutations causing disorders such as cystic fibrosis and spinal muscular atrophy; Panorama™, a non-invasive prenatal test (NIPT) to screen for common chromosomal anomalies in a fetus as early as nine weeks’ gestation; Vistara to screen for single-gene disorders; Evercord™, a cord blood and tissue banking service offered at birth to expectant parents; and Signatera™ (RUO), a personalized circulating DNA assay used in oncology research to identify minimal residual disease, treatment response, and cancer recurrence. Products available through direct sales, laboratory distribution partners or laboratories who license Natera’s cloud-based Constellation™ software system.

NIPD Genetics is an innovative European biotechnology company that designs, develops, and manufactures non-invasive genetic tests in the fields of prenatal, oncology and reproductive health. Founded in 2010, NIPD Genetics leverages proprietary genetic and bioinformatics methods to develop novel technologies for prediction and diagnosis of genetic disorders. NIPD Genetics provides the VERACITY NIPT for the detection of trisomies 21, 18, 13, X and Y aneuploidies and select microdeletions. NIPD Genetics also offers VERAgene, the first comprehensive NIPT that simultaneously screens for aneuploidies, microdeletions and point mutations. VERAgene targets nearly 500 mutations on 50 genes to screen for 50 monogenic disorders.

At Progenity, we provide clear and actionable genetic results that help patients and their families Prepare for Life. Partnering with healthcare providers around the globe to offer the Preparent® Carrier Test. Three test options evaluate carrier status for hereditary disorders that typically affect health in early childhood and include conditions recommended by ACOG. Progenity also offers the Innatal® Prenatal Screen, which provides noninvasive aneuploidy screening for singleton and twin pregnancies with industry-leading sensitivity and specificity and low failure rates. Turn around time for results is typically 5 to 7 days.

Visit us at Booth #11 or at progenity.com.